Clinical Trial Update: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating capivasertib in combination with fulvestrant for locally advanced/inoperable or metastatic HR+/HER2- breast cancer in Chinese patients;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING